4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

The mammalian target of rapamycin (mTOR), a kinase that regulates proliferation and apoptosis, has been extensively evaluated as a therapeutic target in multiple malignancies. Rapamycin analogs, which partially inhibit mTOR complex 1 (mTORC1), exhibit immunosuppressive and limited antitumor activity...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Yun, Seongseok, Vincelette, Nicole D., Knorr, Katherine L. B., Almada, Luciana L., Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Dai, Haiming, Pratz, Keith W., Hess, Allan D., Smith, B. Douglas, Karp, Judith E., Hendrickson, Andrea E. Wahner, Fernandez-Zapico, Martin E., Kaufmann, Scott H.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2016
Subjects:
Lymphoid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891953/
https://ncbi.nlm.nih.gov/pubmed/26917778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-629485
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items